ライフサイエンスコーパス: glycoprotein

1 structural modeling of the SARS-CoV-2 spike glycoprotein.

2 erogeneity impacts the antigenicity of the S glycoprotein.

3 izing humoral immune response, the spike (S) glycoprotein.

4 g cathepsin-mediated processing of the Ebola glycoprotein.

5 n identification at a low microgram level of glycoprotein.

6 5 DENV3 TS mAbs recognizing the envelope (E) glycoprotein.

7 lybasic furin cleavage site in its spike (S) glycoprotein.

8 ERINC5 with remodeling of the HIV-1 envelope glycoprotein.

9 ngaging the receptor-binding domain of the S glycoprotein.

10 t-pass metabolism, and efficient efflux by P-glycoprotein.

11 g irreversible conformational changes in the glycoprotein.

12 llular immune responses to Ebolavirus (EBOV) glycoprotein.

13 taneous interaction between all three of the glycoproteins.

14 thesis and quantitative evaluation of intact glycoproteins.

15 diverse glycans on cell surface and secreted glycoproteins.

16 t glycopeptides (IGPs) derived from N-linked glycoproteins.

17 n of sulfated glycosaminoglycans and charged glycoproteins.

18 sitioned to match the C termini of the viral glycoproteins.

19 y for antibodies reactive with Nipah G and F glycoproteins.

20 ased intact glycopeptide characterization of glycoproteins.

21 uses distinct receptors and receptor-binding glycoproteins.

22 e group of cell surface- and wall-associated glycoproteins.

23 from the OpeRATOR digestion of four known O-glycoproteins.

24 ls, the dopamine D2 receptor, and complement glycoproteins.

25 nvestigated the role of leucine-rich alpha-2-glycoprotein 1 (LRG1) in normal and diabetic wound heali

26 In the randomized cohort, glycoprotein 120 (gp120) substitutions were found in 20

27 annose glycans found on the surface envelope glycoprotein-120 (gp120).

28 GT8, an engineered outer domain of the HIV-1 glycoprotein-120, on DNA origami nanoparticles to system

29 t-that SarA mimics the cytoplasmic domain of glycoprotein 130 (gp130, IL6ST).

30 x 10(-9)), an Asian-specific, nonsynonymous glycoprotein 2 (GP2) gene variant.

31 vivo. Here, we investigated synaptic vesicle glycoprotein 2A (SV2A) levels and their relationship to

32 CB-J, a radioligand for the synaptic vesicle glycoprotein 2A (SV2A), were used to study hippocampal s

33 (ND) Conclusion: The novel synaptic vesicle glycoprotein 2A tracer, (18)F-SynVesT-1, displays excell

34 oclonal antibodies that target the spike (S) glycoprotein(5), and identify several that exhibit poten

35 lactans connected to proteins which form AGP glycoprotein, a macro-molecule responsible for the emuls

36 MGAT1 (Man(5)GlcNAc(2)Asn) to accumulate on glycoproteins, a change that is detected by the lectin G

37 e have uncovered a novel interaction between glycoproteins A33 and A34.

38 Viral glycoproteins A33, A34, and B5 are critical for the effi

39 ecific to the extracellular virion membrane, glycoproteins A33, A34, and B5 are highly conserved amon

40 asma high-sensitivity C-reactive protein and glycoprotein acetyls at 3 consecutive antenatal time poi

41 rnal high-sensitivity C-reactive protein and glycoprotein acetyls at and across all 3 antenatal time

42 Antifreeze glycoproteins (AFGPs) are the most potent IRI.

43 ers C-reactive protein (CRP) and alpha1-acid glycoprotein (AGP) and serum vitamin B-12 and serum and

44 etuin, IgG, ribonuclease B, and alpha-1 acid glycoprotein (AGP) by PGC-LC-MS.

45 and C-reactive protein (CRP) or alpha-1-acid glycoprotein (AGP) was observed: 1) exclude individuals

46 C-reactive protein (hs-CRP), and alpha1-acid glycoprotein (AGP)] for which observational associations

47 and 2 (TNFR1 and TNFR2), CD44, or alpha2-HS glycoprotein (AHSG), all of which are involved in the pa

48 Major surface glycoprotein also down regulated Dectin-1 receptor messe

49 one-binding globulin (SHBG) is a circulating glycoprotein and a regulator of sex hormone levels, whic

50 ion model, we sought to understand the viral glycoprotein and cellular receptor required for EBV-2 in

51 ng of immunity against the coronavirus spike glycoprotein and detail novel pathways to rapidly identi

52 unique glycosylation events belonging to 378 glycoproteins and 604 unique protein sites of glycosylat

53 sed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant.

54 ficient tools used in the current studies of glycoproteins and structure of their glycoforms.

55 is virus (rVSV) vectors expressing filovirus glycoproteins and that also contains a rVSV vector expre

56 rage was obtained for N-glycans derived from glycoproteins and tissue samples after chemical derivati

57 and provides specific immunity against Ebola glycoprotein, and is currently in phase 2 and 3 studies.

58 eRATOR is not fully active toward sialylated glycoproteins, and it has been suggested that this acidi

59 icacy at baseline, and modulation of the KEL glycoprotein antigen occurred to the same extent in the

60 (e.g., glycomics), where limited amounts of glycoproteins are available for analysis.

61 Glycoproteins are particularly challenging in this regar

62 ory pathway, misfolded asparagine (N)-linked glycoproteins are selectively sorted for endoplasmic ret

63 ze the glycocalyx N-glycans and O-glycans of glycoproteins, as well as intact glycolipids in parallel

64 structure and sequence of the homotetrameric glycoprotein avidin.

65 xpressing the human cytomegalovirus antigens glycoprotein B (gB) and the 65-kD phosphoprotein (pp65),

66 silencing and the colocalization of LAMP-1, glycoprotein B (gB) of MDV, and cholesterol (filipin III

67 VZV glycoprotein B (gB) peptides assembled into fibrils and

68 The MF59-adjuvanted glycoprotein B (gB) protein subunit vaccine (gB/MF59) is

69 inst HCMV infection, and the virion envelope glycoprotein B (gB) serves as a major target of neutrali

70 eutralizing mAb RRV-12 in a region of the E2 glycoprotein B domain.

71 In this study, we sought to improve upon the glycoprotein B protein vaccine (gB/MF59), the most effic

72 The human herpesvirus-7 (HHV-7) U21 glycoprotein binds to class I major histocompatibility c

73 vide a way forward for developing diagnostic glycoprotein biomarkers with urine as a noninvasive biol

74 Microarrays revealed that the transmembrane glycoprotein Bone marrow stromal antigen 2 (Bst2) expres

75 erate molecular dynamics simulations of each glycoprotein both alone and interacting with one another

76 ing, revealing a physiological role for this glycoprotein, but that excess LRG1 expression in diabete

77 served reduced plasma levels of zinc-alpha-2-glycoprotein, butyrylcholinesterase, and increased level

78 gambiense surface glycoproteins can be inhibited by circulating antibodies

79 Multivalent presentation of viral glycoproteins can substantially increase the elicitation

80 The glycoprotein CD11b/CD18 plays a well-described role in r

81 The glycoprotein CD83 is known to be expressed by different

82 t with the late endosomal/lysosomal membrane glycoprotein CLN3 (ceroid lipofuscinosis neuronal 3), wh

83 ll growth and differentiation by controlling glycoprotein clustering, signaling, and endocytosis.

84 glycosylation motif in the subunit G1 of the glycoprotein complex of Can, which is otherwise present

85 oteins including HIV-1 envelope, Lassa virus glycoprotein complex, and influenza hemagglutinin, where

86 an intracellular component of the dystrophin glycoprotein complex, directly and robustly promotes the

87 teins have defined the interaction sites for glycoprotein complexes and receptors, and have revealed

88 148, such as modulation of alternative viral glycoprotein complexes that govern the virus' ability to

89 roduction of a clinical HIV vaccine with Env glycoprotein components.IMPORTANCE HIV-1 Env protein is

90 the specific effects of SERINC5 on the HIV-1 glycoprotein conformation may be useful for designing ne

91 ingle-cycle HSV candidate vaccine deleted in glycoprotein-D (DeltagD-2) that induces ADCC provided co

92 ighamoeba infection on fluid secretion and P-glycoprotein-dependent detoxification by desert locust M

93 Coupled with reduced efficiency of P-glycoprotein detoxification per surface area, Malpighamo

94 DC-SIGN-mediated augmentation of Ebola virus glycoprotein-driven cell entry (with IC(50) values down

95 that both host proteases can activate the S glycoprotein during the process of syncytium formation.

96 Glycomics has been used to find affected glycoproteins during depression.

97 Glycoprotein E (gE)-specific humoral and cell-mediated i

98 amma)-producing CD4 T cells specific for VZV glycoprotein E and all other structural and nonstructura

99 The adjuvanted recombinant glycoprotein E herpes zoster (HZ) vaccine is superior to

100 he rod-shaped structures failed to recognize glycoprotein E, the well-known binding partner of gI.

101 r cells is inhibited by co-expression of the glycoprotein E-cadherin.

102 to model a complete ectodomain of the major glycoprotein E2 from three strains of HCV.

103 ally affect the activities and half-lives of glycoproteins, effects that are relevant to understandin

104 How this single viral glycoprotein efficiently redirects the U21/class I MHC c

105 In contrast, pLV pseudotyped both glycoproteins efficiently; however, much higher titers o

106 es with subtype A BG505-derived HIV envelope glycoprotein (Env) immunogens have revealed that the dom

107 scape through mutation of the HIV-1 envelope glycoprotein (Env) limits clinical applications.

108 n of HIV-1 Env.IMPORTANCE The HIV-1 envelope glycoprotein (Env) opens in response to receptor CD4 bin

109 erial conformational changes in the envelope glycoprotein (Env) trimer that result in the fusion of t

110 The HIV-1 envelope glycoprotein (Env) trimer, composed of gp120 and gp41 su

111 Well-ordered HIV-1 envelope glycoprotein (Env) trimers are prioritized for clinical

112 genicity of native-like recombinant envelope glycoprotein (Env) trimers based on viral sequences from

113 obicides that target glycans on the envelope glycoproteins (Envs) of HIV-1.

114 ction with either the myelin oligodendrocyte glycoprotein epitope MOG(35-55) or the full-length recom

115 tigens that have shown promise is aberrant O-glycoprotein epitopes.

116 ence and N-linked glycosylation of influenza glycoproteins, especially hemagglutinin (HA).

117 st that HSV-1 gC protects the viral envelope glycoproteins essential for entry, including gB, by shie

118 Knowledge of the spike glycoprotein evolution, function and interactions with h

119 we demonstrate that the SARS-CoV-2 spike (S) glycoprotein exhibits a high-affinity motif for binding

120 ing to extracellular pathogens, HLA class II glycoproteins, expressed by specialized antigen-presenti

121 ls, where the native glycan presentation and glycoprotein expression are preserved, have significant

122 ained in cancerous kidney tissues with low P-glycoprotein expression.

123 We studied the contribution of several S glycoprotein features to these functions, focusing on th

124 in the calcium binding extracellular matrix glycoprotein fibrillin-1.

125 otein N-linked glycosylation is critical for glycoprotein folding, quality control, trafficking, reco

126 mically released from isolated cell membrane glycoproteins following N-glycan and lipid/glycolipid re

127 system will fuel the development of helminth glycoproteins for pharmaceutical applications or novel a

128 ral pseudoparticles that contain the surface glycoprotein from the pathogenic virus incorporated into

129 These pseudoparticles enter cells using the glycoprotein from the pathogenic virus, leading to a rea

130 so facilitated the novel characterization of glycoproteins from the red alga Cyanidioschyzon merolae.

131 e similar domain connectivity that resembles glycoproteins from unrelated animal-infecting viruses, s

132 ability of protease inhibitors to suppress S glycoprotein function.

133 F), an exceptionally large multimeric plasma glycoprotein, functions to initiate coagulation by agglu

134 Here, we expressed two glycoproteins (FUS4 and FUS8) from ChHV5 using baculovir

135 oteins, including vesicular stomatitis virus glycoprotein G (VSV-G) or baculovirus gp64.

136 ibe the crystal structure of the RSV surface glycoprotein G in complex with a broadly neutralizing hu

137 virus (VSV) recombinants expressing the RABV glycoprotein (G) demonstrated that GRP-60367 inhibits en

138 ent of the viral genome encodes two envelope glycoproteins, G(N) and G(C), which together form the en

139 We found that HCMV glycoproteins gB and gH directly bind and activate cellu

140 Overall, our data indicate that HCMV glycoproteins gB and gH work in concert to initiate an H

141 or the splicing of UL44 transcripts encoding glycoprotein gC, a protein known as being essential for

142 SARS-CoV-2 spike gene in place of the native glycoprotein gene (VSV-eGFP-SARS-CoV-2).

143 and tetraantennary N-glycans of alpha-1-acid glycoprotein generally containing 0 or 1 alpha2-6-linked

144 UDP-glucose:glycoprotein glucosyltransferase (UGGT) 1 and 2 are cent

145 ns highly similar to that of the recombinant glycoprotein glycans.

146 The envelope glycoproteins Gn and Gc form heterodimers that further a

147 us vaccine expressing the Ebola virus (EBOV) glycoprotein (GP) (rVSV-ZEBOV) was successfully used dur

148 granules, dense granule secretion machinery, glycoprotein (GP) VI, or the GPVI signaling effector pho

149 s to the immunodominant NiV receptor-binding glycoprotein (GP), and potently neutralizes NiV, indicat

150 c to the receptor binding site (RBS) of MARV glycoprotein (GP).

151 illness, antibodies predominate to VP40 and glycoprotein (GP).

152 s that cooperatively bound to the ebolavirus glycoprotein (GP).

153 V viral entry inhibitor, via binding to EBOV glycoprotein (GP).

154 acting with their respective viral surfaces (glycoprotein gp120 of HIV and the fivefold axis of the E

155 viruses with mutations in the viral envelope glycoprotein, gp41.

156 Regions within the virus surface glycoprotein (GPC) and nucleoprotein (NP) are the main t

157 The glycoprotein (GPC) gene is primarily responsible for att

158 n gB is nonfusogenic on its own and requires glycoproteins H (gH) and L (gL) for membrane fusion, whi

159 Human cytomegalovirus (HCMV) glycoproteins H and L (gH/gL) can be bound by either gO

160 -infected cells with antibody to the SINV E2 glycoprotein had cell type-specific effects.

161 We found that the SARS-CoV-2 S glycoprotein harbors a furin cleavage site at the bounda

162 Expression of mucin (MUC) glycoproteins has been shown to enhance chemoresistance

163 us (HCMV) and Epstein-Barr virus (EBV) entry glycoproteins have defined the interaction sites for gly

164 dopsin-like G protein-coupled receptors, the glycoprotein hormone receptors (GPHR) have a large extra

165 e results provide insights into SARS-CoV-2 S glycoprotein-host cell interactions that likely contribu

166 beta(2)-Glycoprotein I (beta(2)GPI) is an abundant plasma protei

167 port that, under flow, von Willebrand factor/glycoprotein Ibalpha-dependent platelet 'priming' induce

168 syndromes (NSTEACS) in the EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST

169 first device with consequently higher use of glycoprotein IIb/IIIa inhibitors and thrombus aspiration

170 ant boundary lubricant and chondroprotective glycoprotein in synovial fluid.

171 known as an anti-inflammatory transmembrane glycoprotein in the immunoglobulin superfamily.

172 ptides were successfully identified from 161 glycoproteins in human serum.

173 We performed dose-response, synergism, P-glycoprotein inhibition, and pharmacokinetic studies in

174 tive mass spectrometry to map the glycan and glycoprotein interactors for galectin-3 in live human he

175 stematic optimization and evaluation using a glycoprotein interference model, the SPS/ETD approach wa

176 SV vaccine is an understanding of the virion glycoproteins involved in entry.

177 the case of influenza, the receptor-binding glycoprotein is the haemagglutinin (HA), and following r

178 Influenza hemagglutinin (HA) glycoprotein is the primary surface antigen targeted by

179 rough structure-based design of the envelope glycoproteins is a promising route to an effective vacci

180 , a C-type lectin domain-containing membrane glycoprotein, is selectively expressed on highly activat

181 ting indicate that papilin, a poorly studied glycoprotein, is the most abundant component in the gona

182 IVmac239 was constructed in the context of a glycoprotein L (gL) deletion mutation.

183 ntibody-mediated targeting of the hantaviral glycoprotein lattice.

184 find that targeting the BMME with P-selectin glycoprotein ligand-1 (PSGL-1)-targeted BTZ and ROCK inh

185 ichment of a mutation within UL100 (encoding glycoprotein M) and a specific truncation of glycoprotei

186 ensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M.

187 in basic protein (MBP) and myelin-associated glycoprotein (MAG) myelin proteins were markedly increas

188 elin basic protein(+)/myelin oligodendrocyte glycoprotein(+) mature oligodendrocytes with reciprocal

189 substrates and glycan substrates present on glycoproteins, measured simultaneously, affords a unique

190 binding domain (RBD) of the SARS-CoV-2 spike glycoprotein mediates viral attachment to ACE2 receptor

191 Efficient engagement with the envelope glycoprotein membrane-proximal external region (MPER) re

192 re, we identify the germ cell specific Golgi glycoprotein MGAT4D as a protector of male germ cells fr

193 Thus, the Golgi glycoprotein MGAT4D is a novel, intrinsic protector of m

194 We discuss the placental secretome including glycoproteins, microRNAs and extracellular vesicles as p

195 find that rather than the mass or length of glycoprotein modifications, the stability of DC-SIGN is

196 , disease course, and myelin oligodendrocyte glycoprotein (MOG) antibody (Ab) dynamics between childr

197 pid protein (PLP) and myelin oligodendrocyte glycoprotein (MOG), the membrane proteins found in the m

198 le-Ab-seronegative, 4 myelin oligodendrocyte glycoprotein (MOG)-Ab-seropositive and 4 AQP4-Ab-seroneg

199 gG antibodies against myelin-oligodendrocyte glycoprotein (MOG-IgG) have been increasingly recognised

200 is a posttranslational modification on a few glycoproteins, most commonly in the brain, on the neural

201 Pneumocystis major surface glycoprotein (Msg) is a 120-kD surface protein complex o

202 rs mastigonemes, filamentous polymers of the glycoprotein MST1, to the extracellular surface of Chlam

203 a gel-like material comprised mainly of the glycoprotein mucin and water and it displays both hydrop

204 one of the unique metacyclic variant surface glycoprotein (mVSG) coat protein transcripts identified.

205 Here we present the crystal structure of glycoprotein N (G(N)) from the tomato spotted wilt virus

206 ere correlated with inflammation-attenuating glycoprotein non-metastatic melanoma protein B (GPNMB) s

207 The glycoprotein nonmetastatic melanoma protein B (GPNMB, al

208 olated from papaya, we identified a secreted glycoprotein of 15 kDa, designated as Ppal15kDa, using l

209 t also contains a rVSV vector expressing the glycoprotein of a lineage IV strain of LASV.

210 The E2 glycoprotein of hepatitis C virus (HCV) is the major tar

211 Envelope (Env) glycoprotein of human immunodeficiency virus type 1 (HIV

212 T cells that are reactive against the spike glycoprotein of SARS-CoV-2 in the peripheral blood of pa

213 eral monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which we identified from mem

214 designed a multi-epitope vaccine using spike glycoprotein of SARS-CoV-2.

215 d receptor-binding domain (RBD) of the spike glycoprotein of SARS-CoV-2.

216 Fibronectin (FN) is an essential glycoprotein of the extracellular matrix; binds integrin

217 otein, which show a higher homology to spike glycoproteins of human endemic coronaviruses, compared w

218 d the profile of N-glycans from the salivary glycoproteins of Lutzomyia longipalpis, vector of viscer

219 However, viral glycoproteins often are not readily suited for generatin

220 y to SARS-CoV, SARS-CoV-2 utilises the Spike glycoprotein on the envelope to recognise and bind the h

221 eration of a library of Cys mutations in Env glycoprotein on the viral surface, covalent labeling of

222 roup determinants are expressed on different glycoproteins on platelet surfaces.

223 uclear vesicle-like structures near envelope glycoproteins or mitochondria.

224 treatment by efflux transporters, such as P-glycoprotein (P-gp) at the blood-brain barrier (BBB).

225 to assess the activity of the transporter P-glycoprotein (P-gp) in humans.

226 ug resistance, the drug efflux behavior of P-glycoprotein (P-gp) remains a prominent challenge in can

227 P-glycoprotein (P-gp), also known as ABCB1, is a cell memb

228 P-glycoproteins (Pgp) have been proposed as contributors t

229 s of individual proteins in the collagen and glycoprotein phases of connective tissue extracellular m

230 tigate proteome dynamics in the collagen and glycoprotein phases of connective tissues by exploiting

231 Glycoproteins play a central role in many biological pro

232 dy, we used DNA vaccination against the MACV glycoprotein precursor complex (GPC) and murine hybridom

233 ty in human cells, providing evidence that a glycoprotein precursor variant, present in ticks, has se

234 ms representing those present in the nascent glycoproteins (prior to enzymatic modifications in the G

235 Coronavirus spike (S) glycoproteins promote entry into cells and are the main

236 initiate infection, the SARS-CoV-2 spike (S) glycoprotein promotes attachment to the host cell surfac

237 The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the m

238 NA vaccine encoding the soluble Hendra virus glycoprotein protected up to 70% of Syrian hamsters from

239 posed of a set of collagens, non-collagenous glycoproteins, proteoglycans, and hyaluronan.

240 as9 gene editing identified the inflammatory glycoprotein PTX3 enriched in DXR-elicited sEV as a crit

241 ressed on several different platelet surface glycoprotein receptors.

242 ick-specific amino acid variant in the viral glycoprotein region that dramatically reduces its fusion

243 Although CEACAM1 (CC1) glycoprotein resides at the interface of immune liver in

244 Integrin alpha V (ITGAV), a transmembrane glycoprotein responsible for cell-to-matrix binding has

245 cence reveals that coexpression of all three glycoproteins results in their localization to a juxtanu

246 r (AMT)/methylammonium permease (MEP)/Rhesus glycoprotein (Rh) family of ammonia (NH(3)/NH(4) (+)) tr

247 d overall faster protein turnover within the glycoprotein-rich interfascicular matrix compared to the

248 blast fungus Magnaporthe oryzae(1), powerful glycoprotein-rich mucilage adhesives(2) cement melanized

249 cicular (collagen-rich) and interfascicular (glycoprotein-rich) ECM phases of tendon.

250 glycoprotein M) and a specific truncation of glycoprotein RL13, these did not explain the DIDS resist

251 end, a SAM vaccine encoding the rabies virus glycoprotein (RVG) was used.

252 ding free energy changes of SARS-CoV-2 spike glycoprotein (S protein) and host angiotensin-converting

253 The viral spike glycoprotein (S) of SARS-CoV-2 and the human cellular re

254 SARS-CoV-2 spike glycoprotein (S)-reactive antibodies were detectable usi

255 2+)] ([Ca(2+)](i)) and high-molecular-weight glycoprotein secretion.

256 complete extramembrane portion of the viral glycoprotein shell and allowed a detailed description of

257 he EBOV glycoprotein substituted for the VSV glycoprotein show greater safety and efficacy in targeti

258 Regardless of the level of total glycoprotein-specific immune response detected after vac

259 These were positively associated with glycoprotein-specific T-cell but not immunoglobulin (Ig)

260 c vesicular stomatitis viruses with the EBOV glycoprotein substituted for the VSV glycoprotein show g

261 rehensive characterization of some important glycoproteins, such as tumor biomarkers and recombinant

262 tions in hemagglutinin-esterase fusion (HEF) glycoproteins suggests that antigenic drift may also hav

263 e when the MLD was expressed within the EBOV glycoprotein than when EBOV lacked the mucin-like domain

264 id protein and distinct inserts in the spike glycoprotein that appear to be associated with high case

265 Lastly, we have identified peptides in the S glycoprotein that are likely to be presented in human le

266 (NS1) is a membrane-associated and secreted glycoprotein that functions in flavivirus replication an

267 l fluid (CSF) lipocalin 2 (LCN2), a secreted glycoprotein that has been suggested as mediating neuron

268 fold with distant homology to another CCHFV glycoprotein that is suggestive of a gene duplication ev

269 Abs are glycoproteins that carry a conserved N-linked carbohydra

270 an be obscured by the glycosaminoglycans and glycoproteins that coat pathogenic as well as malignant

271 Arabinogalactan-proteins (AGPs) are glycoproteins that interact with other cell wall polymer

272 ntly, these two features of the SARS-CoV-2 S glycoprotein, the furin cleavage site and D614G, have ev

273 9) pandemic, are focused on SARS-CoV-2 spike glycoprotein, the primary target for neutralizing antibo

274 en activator receptor (suPAR) is a signaling glycoprotein thought to be involved in the pathogenesis

275 ptor binding domain (RBD) of the viral spike glycoprotein tightly (K(D) of 2 nM), and a 2.6- angstrom

276 n of several epitopes of the HCV E2 envelope glycoprotein to engineer its antigenic properties.

277 tor-binding domain within its trimeric spike glycoprotein to human angiotensin-converting enzyme 2.

278 within the Golgi, where it allows ER-escaped glycoproteins to bypass the classical N-glycosylation tr

279 ants and with existing 3D structures of both glycoproteins to generate molecular dynamics simulations

280 xed out of normal proximal tubules through P-glycoprotein transporter while being retained in cancero

281 tivation and regulation of NK cells by Ebola glycoprotein.TRIAL REGISTRATIONClinicalTrials.gov NCT023

282 The respiratory syncytial virus fusion (F) glycoprotein trimer-stabilized in the prefusion conforma

283 ectodomains of influenza, HIV, and RSV viral glycoprotein trimers.

284 est that Platynereis CRZ1/GnRHL1 coordinates glycoprotein turnover and energy homeostasis with growth

285 ific changes in regard to the common urinary glycoprotein, uromodulin.

286 GP-5 (Glycoprotein V), GRN (granulin), and MCAM (melanoma cell

287 ve emerged to suggest that modulation of the glycoprotein VI (GPVI) platelet receptor could be harnes

288 vation of influenza virus hemagglutinin (HA) glycoprotein via cleavage by host cell proteases is esse

289 ll-mediated immune response specific for the glycoproteins was also detected in most of the vaccinate

290 ibutes to the activation of the SARS-CoV-2 S glycoprotein, we evaluated the ability of protease inhib

291 cts interactions with sialylated glycans and glycoproteins, we determined high-resolution crystal str

292 Complex N-glycans from alpha-1-acid glycoprotein were analyzed using this approach, revealin

293 analysis of pancreatic cancer sera, where Tn-glycoproteins were identified.

294 f the humoral immune response, the spike (S) glycoprotein, which mediates cell entry and membrane fus

295 metry proteomics and identified multiple ECM glycoproteins whose expression and function in IgAN is u

296 ogenic targets against the coronavirus spike glycoprotein will provide crucial advances towards the d

297 RAGE exists as a membrane glycoprotein with an ectodomain, a transmembrane helix,

298 own by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats.

299 Fibrinogen is a complex glycoprotein with regulatory roles in hemostasis, tumor

300 ding the binding mechanism of specific virus glycoproteins with cellular receptors, can be useful for